Septodont's Strategic Investment in Balanced Pharma to Revolutionize Dental Anesthetics

Posted: January 20, 2025
Septodont, a global leader in dental anesthetics, has invested in Balanced Pharma to develop innovative drugs that enhance patient comfort and safety during dental procedures. The reformulated flagship drugs, BPI-001 and BPI-002, promise improved pain relief, faster onset, and reliability without changing clinical protocols. These drugs target reduced opioid use and multi-day pain relief after oral surgery. Balanced Pharma's BPI-004, an injectable non-opioid analgesic, aims to provide long-lasting analgesia with minimal side effects. By leveraging proprietary technology, Balanced Pharma is set to transform dental and orthopedic anesthesia, offering significant benefits for dental practitioners and patients.
Views: 18
Sponsors
Townie Perks
Townie® Poll
Who or what do you turn to for most financial advice regarding your practice?
  
The Dentaltown Team, Farran Media Support
Phone: +1-480-445-9710
Email: support@farranmedia.com
©2025 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450